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Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) (1). Indole, the
potent basic pharmacodynamic nucleus, has been reported to possess a wide variety of
biological properties, viz. anti-inflammatory (2–4), analgesic (5), anticonvulsant (6, 7) anti-
bacterial and antifungal (8, 9). On the other hand, novel pyrazolo(3,4-b)indole nucleo-
side analogs have been synthesized from the corresponding 3-formyl-2-chloro and
3-cyano-2-chloro indole nucleosides by treatment with hydrazine hydrate (10) and they
acted as potent and selective inhibitors of human cytomegalovirus (HCMV) in vitro (10).
Moreover, when p-nitrophenylhydrazones of several acetophenones, benzaldehydes and
benzophenones were treated with polyphosphoric acid (PPA) new substances contain-
ing the original nitrogen atoms were isolated from the reaction and were characterized
as nitrophenylindazoles (11). Encouraged by these observations, we synthesized novel
pyrazolo(3,4-b) indole derivatives and evaluated their anti-inflammatory, analgesic as well
as anticonvulsant activities in the hope of obtaining superior pharmacological agents.
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A series of 1,8-dihydro-1-aryl-8-alkyl pyrazolo(3,4-b)indoles
4a–j, 5a–j and 6a–j has been synthesized and tested for
their anti-inflammatory and anticonvulsant activities.
Formation of the pyrazoloindole derivatives was achieved
by treating arylhydrazones of N-alkyl indole-3-carbox-
aldehydes 1a–j, 2a–j and 3a–j with ten times their mass
of polyphosphoric acid as a condensing agent. The newly
synthesized compounds were evaluated for their anti-in-
flammatory, analgesic and anticonvulsant activities com-
pared to indomethacin, flufenamic acid and diazepam as
positive controls. Detailed synthesis, spectroscopic and
toxicity data are reported.
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EXPERIMENTAL
Melting points were determined in open capillary tubes on an Electrothermal 9100
digital melting point apparatus (Büchi, Switzerland) and were uncorrected. Elemental
analyses were performed on a Perkin-Elmer 2400 analyzer (USA) and were found within
± 0.4 % of the theoretical values (Table I). IR spectra were recorded on a Perkin-Elmer 1600
FTIR (USA) in KBr pellets. The 1H NMR spectra were measured with a Bruker Avance
digital spectrophtometer (300 MHz) in DMSO-d6 and chemical shifts were recorded in d
ppm relative to TMS. Mass spectra (EI) were run at 70 eV with a JEOL-JMS-AX500 mass
spectrometer (Japan).
The N-alkylindole-3-carboxaldehydes were prepared as reported (12). Arylhydrazo-
nes 1a, 1b, 2a and 2d were prepared according to previously reported procedures (13).
Arylhydrazones of N-alkylindole-3-carboxaldehydes (1c-j, 2b-j, 3a–j).
General procedure
Amixture of N-alkylindole-3-carboxaldehyde (0.001 mol) and the appropriate aryl-
hydrazine (0.001 mol) was refluxed (2–3 h) in absolute ethanol in the presence of a few
drops of acetic acid. The solvent was evaporated to half of its volume under vacuo. After
cooling, water was added and the formed solid was filtered off, air dried and then crys-
tallized from aqueous ethanol (85 %).
1,8-Dihydro-1-aryl-8-alkyl pyrazolo(3,4-b) indoles (4a-j, 5a-j, 6a-j).
General procedure
Each of aryl hydrazones 1-3 was heated with 10–15 times its mass of polyphospho-
ric acid. Heating was continued under stirring, the temperature was slowly increased to 165
°C and the mixture was kept at this temperature for 2–3 min. Marked darkening of the
mixture was observed. The reaction mixture was cooled, and then diluted with water
and extracted with chloroform. The organic layer was washed with water and then dried
over anhydrous sodium sulphate. The solvent was evaporated and the obtained solid
product was crystallized from 85 % aqueous ethanol.
Biological assay
Animals. – Animals were obtained from the animal house colony of the National
Research Center, Cairo, Egypt. All animals were allowed free access to water and were
kept on a constant standard diet. All procedures involving animals were carried out in
accordance with the guide for the care and use of laboratory animals and were approved
by the Ethics Committee of the National Research Centre (Cairo, Egypt). Adult male al-
bino rats (Harlan Sprague-Dawley, USA), weighing 150–180 g, were fasted for 12 hours
and used for determining the anti-inflammatory activity. Adult Swiss Webster mice of
both sexes (Harlan Sprague-Dawley), weighing 20–25 g, were fasted for 12–24 hours and
used for determining the analgesic and anticonvulsant activities.
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Table I. Physical and analytical properties of the new compounds
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Anti-inflammatory activity. – The inhibitory activity of the studied compounds on
carrageenean-induced rat’s paw edema was determined according to the method of Ob-
kowicz et al. (14). Groups of adult male albino rats, 8 animals each, were orally dosed with
tested compounds at doses of 100, 50, 25 and 5 mg kg–1 one hour before carrageenean
challenge. Foot paw edema was induced by subplantar injection of 0.05 mL of 1 % sus-
pension of carrageenean in saline into the plantar tissue of one hind paw. An equal vo-
lume of saline was injected into the other hind paw and served as a control. The animals
were decapitated four hours after drug administration.
The average mass of edema was estimated for the treated as well as for the control group
and the percentage inhibition of edema was evaluated (15). Indomethacin (5.0 mg kg–1), sus-
pended in saline, was employed as a reference drug against the test compounds.
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Data are expressed as mean ± SEM. The results of carrageenean-induced paw edema
are expressed as percentage of change from the control (pre-drug) values. Differences
between the vehicle control and treatment groups were tested using one-way ANOVA
followed by multiple comparisons by Duncan’s multiple range tests.
Analgesic activity. – The method of Okun et al. (16) was used to induce writhing. The
test compounds and the reference drugs flufenamic acid and indomethacine were pre-
pared as a suspension in 2 % Tween 80. A sensitivity test was carried out one day before
drug administration when the animals were injected (i.p.) with 0.2–0.25 mL of 0.02 %
freshly prepared solution of p-benzoquinone in distilled water. Animals showing writh-
ing to p-benzoquinone within 30 minutes were chosen for studying the analgesic activi-
ty. On the following day, mice were divided into 13 groups of 6 animals each. The drugs
were administered orally according to the following protocol: one group received 2 %
Tween 80 (solvent and negative control), the second group received flufenamic acid as
reference (20 mg kg–1), and the third group received indomethacine (5 mg kg–1), while
the other groups received doses of the tested compounds 100, 50, 25 and 5 mg kg–1. One
hour latter, 0.02 % solution of p-benzoquinone was administered (i.p.). The animals were
observed for 30 minutes after injection of the irritant, during which time the animals
showing writhing were counted (writhing is defined as stretch, torsion to one side,
drawing up of hind leg, retraction of the abdomen, so that the belly touches the floor).
All writhing is considered as a positive response. The analgesic activity was expressed
as the percent protection.
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1 and 4 R X 2 and 5 R X 3 and 6 R X
a H H a H 2,4 (NO2)2 a H 2,4,6 (Cl)3
b CH3 H b CH3 2,4 (NO2)2 b CH3 2,4,6 (Cl)3
c CH2CH3 H c CH2CH3 2,4 (NO2)2 c CH2CH3 2,4,6 (Cl)3
d CH2Ph H d CH2Ph 2,4 (NO2)2 d CH2Ph 2,4,6 (Cl)3
e COPh H e COPh 2,4 (NO2)2 e COPh 2,4,6 (Cl)3
f COC6H4Cl-p H f COC6H4Cl-p 2,4 (NO2)2 f COC6H4Cl-p 2,4,6 (Cl)3
g COC6H4Cl-o H g COC6H4Cl-o 2,4 (NO2)2 g COC6H4Cl-o 2,4,6 (Cl)3
h SO2CH3 H h SO2CH3 2,4 (NO2)2 h SO2CH3 2,4,6 (Cl)3
i SO2Ph H i SO2Ph 2,4 (NO2)2 i SO2Ph 2,4,6 (Cl)3
j SO2C6H4Br-p H j SO2C6H4Br-p 2,4 (NO2)2 j SO2C6H4Br-p 2,4,6 (Cl)3
Scheme 1
Anticonvulsant activity. – Mice of both sexes weighing 20–25 g were used and injec-
ted intraperitoneally with 2 % Tween 80 (control) and 5 mg kg–1 diazepam (reference
drug). Other groups received tested components at doses 5, 25 and 50 mg kg–1. One
hour after the drug administration, animals were stimulated through an ear electrode of
50 mA as a signal stimulator for 0.2 s (17). Characteristic of an electric shock seizure are
a tonic limb flexion for 1 to 2 s, followed by a tonic limb extension for roughly 10 to 12 s,
and finally generalized clonic movement for 12 s. Only abolishment of the hind limb
tonic extensor spasm is recorded as the measure of anticonvulsant potency. The tonic
component is considered abolished if the hind leg extension does not exceed a 90° angle
with the plane of the body. Animals showing protection against convulsion were counted
in each group. The anticonvulsant activity was expressed as the percent protection.
RESULTS AND DISCUSSION
The starting materials, arylhydrazones 1-3 were prepared through the condensation
reaction of N-alkylindole-3-carboxaldehydes with substituted phenylhydrazines in re-
fluxing absolute ethanol.
The structure of the new arylhydrazones 1-3 was confirmed based on their precise
elemental analyses (Table I) and spectroscopic data (Table II). The 1H NMR spectra of
the latter compounds revealed singlet signals at 8.5–8.75 ppm for CH=N and singlet sig-
nals from 7.9 to 8.2 ppm for H-2 of indole nucleus, besides other signals (Table II). For
example, the 1H NMR spectrum of compound 1c revealed signals at 9.8 (s, 1H, NH, ex-
changeable with D2O), 8.75 (s, 1H, CH=N), 8.2 (s, 1H, H-2 indole), 7.2–7.8 (m, 9H, aro-
matic protons), 4.0 (q, 2H, CH2) and 1.9 ppm (t, 3H, CH3). Its IR spectrum showed
absorption bands at 3330 (NH), 1680 (C=N) and 1660 cm–1 (C=C).
Treatment of compounds 1-3 with polyphosphoric acid as a condensing agent at
150–165 °C for 2–3 min led to the formation of 1,8-dihydro-1-phenyl-8-alkyl-pyrazolo
(3,4-b) indoles (4a-j), 1,8-dihydro-1-(2,4-dinitrophenyl)-8-alkyl-pyrazolo(3,4-b) indoles
(5a-j) and 1,8-dihydro-1-(2,4,6-trichlorophenyl)-8-alkyl-pyrazolo(3,4-b) indoles (6a-j), res-
pectively, in good yield (44–66 %). The structure of the products was supported by pre-
cise element analyses (Table I), IR, 1H NMR and mass spectral data (Table II).
There is no doubt about the proposed structure of the new target compounds pyra-
zoloindoles 4-6. First, the absence of NH absorption bands in the IR spectra of com-
pounds 4-6 which appeared in the starting ones 1-3. Second, their 1H NMR spectra lack
the singlet signals at d 7.9–8.2 ppm of H-2 indole nucleus and singlet signals of the anilic
protons, and revealed new singlet signals at d 7.6–7.8 ppm of the pyrazole ring. This is a
good evidence for the proposed structures 4-6. For example, the IR spectrum of com-
pound 4c showed absorption bands at 1620 (C=N) and 1600 cm–1 (C=C). Its 1H NMR
spectrum revealed signals at d 7.71 (s, 1H, H-pyrazole), 7.0–7.56 (m, 9H, Ar-H), 4.0 (q,
2H, CH2) and 1.6 ppm (t, 3H, CH3). Its mass spectrum is in accordance with the pro-
posed structure, which showed a molecular ion peak at m/z = 261 (65 %) and a base peak
at m/z = 105 (100 %) besides the other fragments, as illustrated in Table II. The physical
and analytical data of the target compounds 4-6 are given in Table I and the spectro-
scopic data in Table II.
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–1) 1H NMR (d, ppm) Mass (m/z, %)
1c 3330 (NH), 1680
(C=N), 1660 (C=C)
9.8 (s, 1H, NH), 8.75 (s, 1H,
CH=N), 8.2 (s, 1H, H-2 indole),
7.02–7.87 (m, 9H, Ar-H), 4.0
(q, 2H, CH2), 1.9 (t, 3H, CH3)
263 [M+] (51), 156 (32),
144 (20), 105 (100), 77 (60)
1d 3228 (NH), 1620
(C=N), 1601 (C=C)
9.5 (1H, s, NH), 8.75 (1H, s,
CH=N), 8.2 (1H, s, H-2
indole), 7.02–7.54 (14H, m,
Ar-H), 5.5 (2H, s, CH2)
325 [M+] (25), 142 (30),
115 (60), 105 (100), 91(60)
1e 3218 (NH), 1670
(C=O), 1620 (C=N),
1577 (C=C)
9.3 (s, 1H, NH), 8.75 (s, 1H,
CH=N), 8.1 (s, 1H, H-2 indole),
7.01–7.48 (m, 14H, Ar-H)
1f 3232 (NH), 1678
(C=O), 1620 (C=N),
1577 (C=C), 740 (Cl)
9.3 (s, 1H, NH), 8.54 (s, 1H,
CH=N), 8.1 (s, 1H, H-2 indole),
7.01–7.48 (m, 13H, Ar-H)
373 [M+] (10), 375 [M++2] (3),
193 (40), 105 (100), 77 (60)
1g 3222 (NH), 1675
(C=O), 1620 (C=N),
1578 (C=C), 740 (Cl)
9.8 (s, 1H, NH), 8.54 (s, 1H,
CH=N), 8.1 (s, 1H, H-2 indole),
7.01–7.58 (m, 13H, Ar-H)
1h 3218 (NH), 1621
(C=N), 1598 (C=C),
1180&1380 (SO2)
9.8 (s, 1H, NH), 8.55 (s, 1H,
CH=N), 8.1 (s, 1H, H-2
indole), 7.02–7.58 (m, 9H,
Ar-H), 2.81 (s, 3H, CH3)
313 [M+] (56), 220 (30),
142 (100), 107 (10), 105 (20)
1i 3225 (NH), 1621
(C=N), 1578 (C=C),
1181&1365 (SO2)
9.9 (s, 1H, NH), 8.54 (s, 1H,
CH=N), 8.12 (s, 1H, H-2 indole),
7.02–7.48 (m, 14H, Ar-H)




9.7 (s, 1H, NH), 8.54 (s, 1H,
CH=N), 8.12 (s,1H, H-2 indole),
7.01–7.58 (m, 13H, Ar-H)
374 [M+] (20), 376 [M++2] (18),




9.9 (s, 1H, NH), 8.45 (s, 1H,
CH=N), 8.21 (s, 1H, H-2
indole), 7.01–7.77 (m, 7H,




9.87 (s, 1H, NH), 8.55 (s, 1H,
CH=N), 8.21 (s,1H, H-2 indole),
7.01–7.57 (m, 7H, Ar-H), 4.1
(q, 2H, CH2), 1.6 (t, 3H, CH3)
339 [M+] (10), 195 (10),
156 (60), 130 (100), 105 (20)
2e 3228 (NH), 1678
(C=O), 1621 (C=N),
1575 (C=C)
9.5 (s, 1H, NH), 8.55 (s, 1H,
CH=N), 8.2 (s, 1H, H-2 indole),
7.01–7.55 (m, 12H, Ar-H)
2f 3330 (NH), 1698
(C=O), 1620 (C=N),
1575 (C=C), 740 (Cl)
9.9 (s, 1H, NH), 8.54 (s, 1H,
CH=N), 8.1 (s, 1H, H-2 indole),
7.01–7.48 (m, 11H, Ar-H)
463 [M+](3), 465 [M++2] (0.7),
195 (20), 117 (100), 105 (70)
2g 3330 (NH), 1670
(C=O), 1622 (C=N),
1545 (C=C), 740 (Cl)
9.9 (s, 1H, NH), 8.75 (s, 1H,
CH=N), 8.12 (s, 1H, H-2 indole),
7.01–7.58 (m, 11H, Ar-H)
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–1) 1H NMR (d, ppm) Mass (m/z, %)
2h 32181 (NH), 1621
(C=N), 1578 (C=C),
1181&1365 (SO2)
10.1 (s, 1H, NH), 8.75 (s, 1H,
CH=N), 7.99 (s, 1H, H-2
indole), 7.02–7.58 (m, 7H,
Ar-H), 2.81 (s, 3H, CH3)
2i 3219 (NH), 1628
(C=N), 1548 (C=C),
1185&1375 (SO2)
9.3 (s, 1H, NH), 8.54 (s, 1H,
CH=N), 8.2 (s, 1H, H-2 indole),
7.02–7.48 (m, 12H, Ar-H)
465 [M+] (30), 193 (60), 142
(100), 105 (30), 77 (61)




9.9 (s, 1H, NH), 8.54 (s, 1H,
CH=N), 8.21 (s, 1H, H-2 indole),




9.3*&9.9* (2s, 2H, 2NH), 8.55
(s, 1H, CH=N), 8.21 (s, 1H, H-2
indole), 7.01–7.47 (m, 6H, Ar-H)
337 [M+](20), 339 [M++2] (17),
401 [M++4] (9), 403 [M++6]




9.7 (s, 1H, NH), 8.55 (s, 1H,
CH=N), 8.21 (s, 1H, H-2
indole), 7.01–7.47 (m, 6H,




9.77 (s, 1H, NH), 8.45 (s, 1H,
CH=N), 8.2 (1H s, H-2 indole),
7.01–7.57 (m, 6H, Ar-H), 4.2




9.3 (s, 1H, NH), 8.7 (s, 1H,
CH=N), 8.2 (s, 1H, H-2
indole), 7.0–7.55 (m, 11H,
Ar-H), 5.56 (s, 2H, CH2)
427 [M+] (10), 429 [M++2] (7),
431 [M++4] (1), 433 [M++6]
(0.2), 232 (30), 105 (40), 91 (100)
3e 3222 (NH), 1699
(C=O), 1621 (C=N),
1545 (C=C)
9.3 (s, 1H, NH), 8.55 (s, 1H,
CH=N), 8.2 (s, 1H, H-2 indole),
7.01–7.75 (m, 11H, Ar-H)
3f 3333 (NH), 1678
(C=O), 1621 (C=N),
1545 (C=C), 741 (Cl)
10.2 (s, 1H, NH), 8.54 (s, 1H,
CH=N), 8.1 (s, 1H, H-2 indole),
7.01–7.55 (m, 10H, Ar-H)
475 [M+] (10), 477 [M++2] (7),
479 [M++4] (1), 481 [M++6] (0.2),
232 (30), 117 (100), 105 (20)
3g 3350 (NH), 1679
(C=O), 1622 (C=N),
1575 (C=C), 751 (Cl)
9.99 (s, 1H, NH), 8.45 (s, 1H,
CH=N), 8.12 (s, 1H, H-2 indole),
7.01–7.58 (m, 10H, Ar-H)
3h 3219 (NH), 1622
(C=N), 1535 (C=C),
1181&1357 (SO2)
10.1 (s, 1H, NH), 8.45 (s, 1H,
CH=N), 8.0 (s, 1H, H-2
indole), 7.01–7.48 (m, 7H,
Ar-H), 2.81 (s, 3H, CH3)
414 [M+] (16), 416 [M++2] (9),
418 [M++4] (3), 420 [M++6] (0.7),
231 (30), 142 (100), 105 (20)
3i 3235 (NH), 1622
(C=N), 1554 (C=C),
1181&1385 (SO2)
9.5 (s, 1H, NH), 8.54 (s, 1H,
CH=N), 8.2 (s, 1H, H-2 indole),
7.01–7.58 (m, 11H, Ar-H)
3j 3218 (NH), 1621 (C=N),
1557 (C=C), 1137&
1375 (SO2), 758 (Br)
8.9 (s, 1H, NH), 8.50 (s, 1H,
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–1) 1H NMR (d, ppm) Mass (m/z, %)
4a 3280 (NH), 1620
(C=N), 1599 (C=C)
9.1 (s, 1H, NH),
7.67 (s, 1H, H-pyrazole),
7.0–7.45 (m, 9H, Ar-H)
233 [M+] (35), 129 (6),105
(100), 93 (10), 77 (50)
4b 1628(C=N),
1601 (C=C)
7.71(s, 1H, H-pyrazole), 7.0–7.47
(m, 9H, Ar-H), 3.2 (s, 3H, CH3)
247 [M+] (10), 129 (10), 105
(100), 77 (30), 52 (10)
4c 1620 (C=N),
1600 (C=C)
7.71 (s, 1H, H-pyrazole),
7.0–7.56 (m, 9H, Ar-H), 4.0
(q, 2H, CH2), 1.6 (t, 3H, CH3)




7.78 (s, 1H, H-pyrazole),
7.0–7.56 (m, 14H, Ar-H),
5.56 (s, 2H, CH2)
323 [M+] (30), 209 (10), 105
(10), 91 (100), 77 (60), 78 (40)
4e 1678 (C=O), 1620
(C=N), 1578 (C=C)
7.76 (s, 1H, H-pyrazole),
7.0–7.58 (m, 14H, Ar-H)
337 [M+] (20), 309 (2), 140
(10), 139 (100), 77 (40)
4f 1676 (C=O), 1618
(C=N), 1575 (C=C),
740 (Cl)
7.78 (s, 1H, H-pyrazole),
7.0–7.48(m, 13H, Ar-H)
371 [M+] (8), 373 [M++2] (2),
309 (10), 191 (100), 105 (2),
77(60)
4g 1670 (C=O), 1620
(C=N), 1601 (C=C),
741 (Cl)
7.78 (s, 1H, H-pyrazole),
7.0–7.50(m, 13H, Ar-H)
371 [M+] (10), 373 [M++2] (3),
336 (30), 231 (100), 105 (10), 77
(40)





2.81 (s, 3H, SO2CH3)
311 [M+] (25), 207 (20), 129
(30), 105 (100), 77 (50)
4i 1618 (C=N), 1598
(C=C), 1180&1380
(SO2)
7.80 (s, 1H, H-pyrazole),
7.0–7.58(m, 14H, Ar-H)
373 [M+] (15), 269 (18), 243 (20),
141 (100), 105 (10), 77 (20)
4j 1618 (C=N), 1601
(C=C), 1180&1380
(SO2), 780 (Br)
7.80 (s, 1H, H-pyrazole),
7.0–7.58(m, 13H, Ar-H)
451 [M+] (40), 453 [M++2] (3),
241 (100), 105 (10), 77 (50)
5a 3128 (NH), 1635
(C=N), 1578 (C=C)
9.3 (s, 1H, NH),
7.77 (s, 1H, H-pyrazole),
7.0–7.45 (m, 7H, Ar-H)
323 [M+] (45), 195 (30), 167




7.0–7.47 (m, 7H, Ar-H),
3.2 (s, 3H, CH3)
337 [M+] (14), 195 (100), 167
(20), 129 (20), 76 (10)
5c 1635 (C=N),
1545 (C=C)
7.78 (s, 1H, H-pyrazole),
7.0–7.58 (m, 7H, Ar-H), 4.1
(q, 2H, CH2), 1.9 (t, 3H, CH3)




7.67 (s, 1H, H-pyrazole),
7.0–7.48 (m, 12H, Ar-H),
5.56 (s, 2H, CH2)
413 [M+] (35), 195 (40), 129
(20), 91 (100), 76 (10)
5e 1680 (C=O), 1620
(C=N), 1545 (C=C)
7.67 (s, 1H, H-pyrazole),
7.0–7.61 (m, 12H, Ar-H)
427 [M+] (35), 193 (100), 195 (10),
167 (20), 105 (30), 77 (20)
5f 1678 (C=O), 1618
(C=N), 1545 (C=C),
740 (Cl)
7.77 (s, 1H, H-pyrazole),
7.0–7.48 (m, 11H, Ar-H)
461[M+] (15), 463 [M++2] (4), 167
(20), 117 (100), 111/113 (8/2)
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–1) 1H NMR (d, ppm) Mass (m/z, %)
5g 1678 (C=O), 1620
(C=N), 1578 (C=C),
741 (Cl)
7.76 (s, 1H, H-pyrazole),
7.0–7.46 (m, 11H, Ar-H)
461 [M+] (35), 463 [M++2] (17),
265 (100), 167 (20), 76 (40)
5h 1628 (C=N), 1601
(C=C), 1180&1380
(SO2)
7.78 (s, 1H, H-pyrazole),
7.0–7.56 (m, 7H, Ar-H),
2.81 (3H, s, SO2CH3)
5i 1618 (C=N), 1598
(C=C), 1180&1380
(SO2)
7.77 (s, 1H, H-pyrazole),
7.0–7.48 (m, 12H, Ar-H)
5j 1620 (C=N), 1578
(C=C), 1180&1380
(SO2), 780 (Br)
7.81 (s, 1H, H-pyrazole),
7.0–7.48 (m, 11H, Ar-H)
6a 3228 (NH), 1620
(C=N), 1601 (C=C),
741 (Cl)
9.3 (s, 1H, NH),
7.78 (s, 1H, H-pyrazole),
7.0–7.46 (m, 6H, Ar-H)
335 [M+] (30), 337 [M++2] (30),
339 [M++4] (9), 401 [M++6] (1),
111/113 (8/2), 117 (100), 77 (60)
6b 1635 (C=N),
1601(C=C), 740 (Cl)
7.78 (s, 1H, H-pyrazole),
7.0–7.45 (m, 6H, Ar-H),
3.1 (s, 3H, CH3)
6c 1635 (C=N), 1545
(C=C), 741 (Cl)
7.77 (s, 1H, H-pyrazole),
7.0–7.48 (m, 6H, Ar-H), 4.1
(q, 2H, CH2), 1.6 (t, 3H, CH3)
6d 1646 (C=N), 1578
(C=C), 741 (Cl)
7.77 (s, 1H, H-pyrazole),
7.0–7.48 (m, 11H, Ar-H),
5.56 (s, 2H, CH2)
6e 1678 (C=O), 1620
(C=N), 1575 (C=C),
741 (Cl)
7.67 (s, 1H, H-pyrazole),
7.0–7.61 (m, 11H, Ar-H)
6f 1700 (C=O), 1620
(C=N), 1575 (C=C),
740 (Cl)
7.81 (s, 1H, H-pyrazole),
7.0–7.48 (m, 10H, Ar-H)
6g 1698 (C=O), 1620
(C=N), 1575 (C=C),
740 (Cl)
7.80 (s, 1H, H-pyrazole),
7.0–7.58 (m, 10H, Ar-H)
473 [M+] (30), 475[M++2] (24),
477 [M++4] (18), 479 [M++6] (3),
111/113 (10/2), 191 (100), 76 (20)
6h 1620 (C=N), 1578
(C=C), 1180&1380
(SO2), 750 (Cl)
7.77 (s, 1H, H-pyrazole),
7.0–7.56 (m, 6H, Ar-H),
2.81 (s, 3H, SO2CH3)
6i 1621 (C=N), 1575
(C=C), 1180&1380
(SO2), 748 (Cl)
7.80 (s, 1H, H-pyrazole),
7.0–7.55 (m, 11H, Ar-H)
475 [M+] (45), 477[M++2] (40),
479 [M++4] (18), 481 [M++6]
(1), 255 (30), 191 (10),109 (100)




7.81 (s, 1H, H-pyrazole),
7.0–7.45 (m, 10H, Ar-H)
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a Negative control: saline; also solvent for test compounds and indomethacin.













































a p-Benzoquinone was used for inducing writhing in mice.
b Negative control: 2 % Tween 80; also solvent test compounds and reference drugs.
The newly synthesized compounds 4-6 were evaluated for their anti-inflammatory
activity against carrageenean induced rat’s paw oedema by administration of 100, 50, 25
and 5 mg kg–1 (p.o.) using indomethacin as a reference drug (5 mg kg–1). None of the
tested compounds showed antiinflammatory activity at doses of 3 and 5 mg kg–1, whe-
reas compounds 4e, 4f, 4g, 4j, 5d, 5g, 6d, 6f, 6g and 6j exhibited remarkable anti-inflam-
matory activity ranging from 30 to 65 % at a dose of 50 mg kg–1 and from 54 to 78 % at a
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4a 50 33 5f 50 66
25 0 25 50
4b 50 33 5g 50 66
25 0 25 50
4c 50 33 5h 50 50
25 0 25 33
4d 50 33 5i 50 33
25 0 25 16
4e 50 33 5j 50 66
25 0 25 33
4f 50 66 6a 50 50
25 50 25 33
4g 50 66 6b 50 33
25 50 25 16
4h 50 16 6c 50 33
25 16 25 16
4i 50 16 6d 50 33
25 16 25 33
4j 50 50 6e 50 33
25 33 25 33
5a 50 33 6f 50 66
25 16 25 50
5b 50 33 6g 50 83
25 16 25 50
5c 50 33 6h 50 16
25 16 25 0
5d 50 33 6i 50 16
25 16 25 0
5e 50 66 6j 50 66
25 33 25 33
Negative controla 0 0
Diazepam 5 50
a Negative control: 2 % Tween 80; also solvent for test compounds and diazepam.
dose of 100 mg kg–1. The results of the tested compounds are given in (Table III). Higher
anti-inflammatory activity of the previously mentioned compounds compared to the
others may be due to the presence of the halo atoms in their skeletons. The most potent
compounds were 6g and 4g with anti-inflammatory activity of 85 and 79 % at a dose of
100 mg kg–1 and 70 and 64 % at a dose of 50 mg kg–1, respectively.
None of the tested components showed analgesic activity at doses of 25 and 5 mg kg–1,
but the chosen compounds showed remarkable analgesic activity at a dose of 100 mg kg–1
(Table IV). Compounds 4e, 4f, 4g, 4j, 6d, 6f, 6g and 6j showed higher activity at a dose of
100 mg kg–1 than the reference drug flufenamic acid at a dose of 20 mg kg–1. The protec-
tion of these compounds ranged from 66 to 100 %, while compounds 4f and 6f, at a dose
of 50 mg kg–1, showed the same analgesic activity as the reference drug flufenamic acid.
From the data in Table IV it is clear that only compounds 6f and 6g showed high analge-
sic activity at a dose of 50 mg kg–1 of 67 and 83 %, while at a dose of 25 mg kg–1 they
showed 33 and 50 % protection.
Compounds 4-6 exhibited remarkable anticonvulsant activity (Table V). Com-
pounds 4f, 4g, 5f, 5g, 5j, 6f, 6g and 6j at a dose of 50 mg kg–1 showed anticonvulsant
activity higher than that of diazepam at 5 mg kg–1. On the other hand, compounds 4f,
4g, 5f, 5g, 6f and 6g at a dose of 25 mg kg–1 showed 50 % anticonvulsant protection as
did the reference drug diazepam at 5 mg kg–1. None among the tested compounds
showed anticonvulsant activity at a dose of 5 mg kg–1.
CONCLUSIONS
The newly synthesized compounds 1,8-dihydro-1-aryl-8-alkyl pyrazolo(3,4-b)indoles
4, 5 and 6a–j showed remarkable anti-inflammatory, analgesic and anticonvulsant activi-
ties. The presence of the halogen atoms in their skeletons seem to be essential for these
activities.
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S A @ E T A K
Sinteza, protuupalno, analgetsko i antikonvulzivno djelovanje
1,8-dihidro-1-aril-8-alkil pirazolo(3,4-b)indola
ADEL H. MANDOUR, ESLAM R. EL-SAWY, KAMEL H. SHAKER i MOHAMED A. MUSTAFA
Serija 1,8-dihidro-1-aril-8-alkil pirazolo(3,4-b)indola 4a-j, 5a-j i 6a-j sintetizirana je i
testirana na protuupalno i antikonvulzivno djelovanje. Pirazolindol derivati pripravljeni
su reakcijom arilhidrazona N-alkil indol-3-karboksaldehida 1a-j, 2a-j i 3a-j s deset puta
ve}om masom polifosforne kiseline kao sredstva za kondenzaciju. Novosintetizirani
spojevi testirani su na protuupalno, analgetsko i antikonvulzivno djelovanje i uspore-
|eni s djelovanjem indometacina, flufenaminske kiseline i diazepama. U radu su dati
detaljni sintetski, spektroskopski i toksikolo{ki podaci.
Klju~ne rije~i: indol-3-karboksaldehid, protuupalno djelovanje, antikonvulzivno djelovanje, analget-
sko djelovanje
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